Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season.
Nanopore
antiviral drug resistance
diagnosis
genetic diversity
influenza
metagenomics
nosocomial transmission
respiratory viruses
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
8
2021
Statut:
ppublish
Résumé
BackgroundInfluenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy, and supporting infection-control interventions.AimTo evaluate the applicability of this sequencing approach as a routine laboratory test for influenza in clinical settings.MethodsWe conducted Oxford Nanopore Technologies (Oxford, United Kingdom (UK)) metagenomic sequencing for 180 respiratory samples from a UK hospital during the 2018/19 influenza season, and compared results to routine molecular diagnostic standards (Xpert Xpress Flu/RSV assay; BioFire FilmArray Respiratory Panel 2 assay). We investigated drug resistance, genetic diversity, and nosocomial transmission using influenza sequence data.ResultsCompared to standard testing, Nanopore metagenomic sequencing was 83% (75/90) sensitive and 93% (84/90) specific for detecting influenza A viruses. Of 59 samples with haemagglutinin subtype determined, 40 were H1 and 19 H3. We identified an influenza A(H3N2) genome encoding the oseltamivir resistance S331R mutation in neuraminidase, potentially associated with an emerging distinct intra-subtype reassortant. Whole genome phylogeny refuted suspicions of a transmission cluster in a ward, but identified two other clusters that likely reflected nosocomial transmission, associated with a predominant community-circulating strain. We also detected other potentially pathogenic viruses and bacteria from the metagenome.ConclusionNanopore metagenomic sequencing can detect the emergence of novel variants and drug resistance, providing timely insights into antimicrobial stewardship and vaccine design. Full genome generation can help investigate and manage nosocomial outbreaks.
Identifiants
pubmed: 34240696
doi: 10.2807/1560-7917.ES.2021.26.27.2000004
pmc: PMC8268652
doi:
Substances chimiques
Antiviral Agents
0
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862332
Virology. 2009 Jun 5;388(2):270-8
pubmed: 19394063
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1315-20
pubmed: 23302696
PLoS One. 2017 Nov 7;12(11):e0187780
pubmed: 29112950
Nature. 2016 Feb 11;530(7589):228-232
pubmed: 26840485
Nat Methods. 2015 Aug;12(8):733-5
pubmed: 26076426
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
N Engl J Med. 2011 Dec 29;365(26):2541-2
pubmed: 22204735
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Antiviral Res. 2016 Aug;132:178-85
pubmed: 27265623
J Infect Dis. 2018 Sep 22;218(9):1485-1489
pubmed: 29873767
Science. 2003 Nov 28;302(5650):1519-22
pubmed: 14645836
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Euro Surveill. 2018 Apr;23(15):
pubmed: 29667576
Antiviral Res. 2015 May;117:27-38
pubmed: 25721488
Clin Infect Dis. 2019 Oct 30;69(10):1649-1656
pubmed: 30993315
J Infect. 2020 May;80(5):571-577
pubmed: 32092386
BMC Genomics. 2018 Sep 27;19(1):714
pubmed: 30261842
Genome Res. 2016 Dec;26(12):1721-1729
pubmed: 27852649
Trends Biotechnol. 2020 Apr;38(4):360-367
pubmed: 31810633
Vaccine. 2008 Sep 12;26 Suppl 4:D49-53
pubmed: 19230160
Nat Protoc. 2017 Jun;12(6):1261-1276
pubmed: 28538739
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Gen Virol. 2003 Sep;84(Pt 9):2285-2292
pubmed: 12917448
Antiviral Res. 2018 Sep;157:38-46
pubmed: 29981793
Science. 2019 Jan 4;363(6422):74-77
pubmed: 30606844
Mol Biol Evol. 2007 Aug;24(8):1811-20
pubmed: 17522084
Genome Med. 2015 Sep 29;7:99
pubmed: 26416663
Nat Biotechnol. 2019 Jul;37(7):783-792
pubmed: 31235920
Lancet Infect Dis. 2018 Jul;18(7):697
pubmed: 29976515
Front Microbiol. 2018 Sep 19;9:2225
pubmed: 30283430
Microbiol Rev. 1992 Mar;56(1):152-79
pubmed: 1579108
J Clin Microbiol. 2019 Dec 23;58(1):
pubmed: 31666364
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373